Back to results
US 10,821,174 B2Granted
Recombinant Hansenula polymorpha-based high dosage hepatitis B vaccine
AssigneeHemu Wang
InventorsHemu Wang, Changhua Wang, Jun Yang
Life of this patent
Estimating the term…
Abstract
Provided is a recombinant Hansenula polymorpha-based high dosage hepatitis B vaccine, an HBsAg pure stock solution yield of a recombinant Hansenula polymorpha fermentation broth used for producing the hepatitis B vaccine being 300 mg/L-400 mg/L.
Claims11
A hepatitis B vaccine comprising a recombinant Hansenula polymorpha, comprising and expressing hepatitis B surface antigen (HBsAg) of SEQ ID NO:
- 1, wherein a host Hansenula polymorpha cell line of the recombinant Hansenula polymorpha is HU-11, and the accession number of the host Hansenula polymorpha cell line is CGMCC No.1218, and a disrupted DNA sequence of an orotidine-5-phosphate decarboxylase gene of the host Hansenula polymorpha is SEQ ID NO:
- 3, wherein the dose of the HBsAg in the hepatitis B vaccine is 40 pg/dose for adults and 20 pg/dose for children, and wherein the pure stock solution yield of the hepatitis B vaccine is 300 mg/L fermentation liquid to 400 mg/L fermentation liquid.
A recombinant Hansenula polymorpha, wherein the recombinant Hansenula polymorpha comprises the nucleotide sequence of SEQ ID NO:
- 1, and the nucleotide sequence of SEQ ID NO:
- 1 is integrated into the genome of the recombinant Hansenula polymorpha, wherein a host Hansenula polymorpha cell line of the recombinant Hansenula polymorpha is HU-11, and the accession number of the host Hansenula polymorpha cell line is CGMCC No.1218, and a disrupted DNA sequence of an orotidine-5-phosphate decarboxylase gene of the host Hansenula polymorpha is SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.